<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211117053090N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-01-22</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>The effect of aroma with  rose damascena essence on nausea and vomiting of chemotherapy</public_title>
      <acronym></acronym>
      <scientific_title>Effect of aromatherapy with rosa Damascena essence on nausea and vomiting in patients with breast cancer undergoing chemotherapy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-01-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>76</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60088</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Samples are entered into the study by non-random(purposive) sampling according to the inclusion criteria.In this study, we will use the Restricted randomization method of block randomization. Blocked randomization is usually used to balance the number of samples allocated to each of the studied groups. This feature helps researchers to equalize the number of samples allocated to each of the studied groups in cases where basics analysis are required during the sampling process. All blocks are the same size, and in this two-group experiment we will have blocks of size 4 (including 2 participants in the intervention group and2 participants in the control group). Random allocation software is also used for randomization. These random sequence generation software in addition to simple randomization, are able to generate sequences by blocking method. To conceal, we use Allocation concealment, is a technique that ensures that random allocation sequences are performed without knowing which patient will receive which treatment. Using sealed envelopes with random sequence (envelopes opaque, sealed, numbered sequentially),each of the random sequences created is recorded on a card and the cards are placed inside the envelopes. In order to maintain the random sequence, numbering is done on the outer surface of the envelopes in the same way. Finally, the lids of the letter envelopes are glued and placed inside a box، respectively, Blinding description: After obtaining the written consent of the participants, the prepared packages including (dropper containing distilled water, rose essence in the same shape and size as in the paper packages, pads and pins) will be given to the patients after the completion of their chemotherapy. They are taught how to use the contents of the package at home. In this way, there is no communication and contact between the participants of the intervention and control group. No odor from the dropper can be spread in the hospital that cover with a paper box. 
1. One who ( except researcher) accommodate the provided packets in the same shapes and sizes to the patients، whether the which packet is placebo or intervention is uninformed.
2. The person involved in information analysis is not involved in collecting information after the intervention.
3. The person who contacts the participants to evaluate the outcome of the intervention is unaware of the allocation of participants into two groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Chemotherapy-induced nausea and vomiting in breast cancer.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 38 women with breast cancer participated in the study according to the inclusion criteria. Each participant was given a package containing 20ml dropper bottle (containing rose essence prepared by parsian (Medina Al-Nabi) Company with a purity of 40%) ، three pads (10 *10 cm ) and a pin. After completing chemotherapy ،it should be taugh to pour 6 drops of dropper bottle content after going to home،which include rose essence of 40%purity on the pad and every given pad for every turn،before serving each main meal(morning, noon, and night) during 24 hours in a 30cm distant of their nose attached to their collar of clothes by a pin.This procedure was performed three times a day (morning, noon, and night). After the intervention (24 hours after chemotherapy), by phone Or face-to-face، Rhodes and VAS questionnaires are filled out to measure nausea and vomiting and sent to the data analyst. Intervention 2: Control group: 38 women with breast cancer who participated in the study according to inclusion criteria. A package containing a 20 ml dropper bottle ( containing distilled water), three pads (10 x 10 cm) and a pin given to participants . After completing chemotherapy it shoud be taugh  to Pour 6 drops of the contents of the dropper bottle after going to home،which include distilled water on the pad and every given pad for every turn،before serving each main meal(morning, noon, and night) during 24 hours in a 30cm distant of their nose attached to their collar of clothes by a pin.This procedure was performed three times a day (morning, noon, and night) After the intervention (24 hours after chemotherapy), by phone Or face-to-face Rhodes and VAS questionnaires are filled out to measure nausea and vomiting and sent to the data analyst.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Kiarash Tabaraei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 182, Nabi Akram Alley, East Ferdowsi St, Postal Code 6861944468</address>
        <city>Aligudarz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6861944468</zip>
        <telephone>+98 66 4332 3985</telephone>
        <email>kiarashtabaraei@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Kiarash Tabaraei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 182, Nabi Akram Alley, East Ferdowsi St., Postal Code 6861944468</address>
        <city>Aligoudarz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6861944468</zip>
        <telephone>+98 66 4332 3985</telephone>
        <email>kiarashtabaraei@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Definitive diagnosis of breast cancer by oncologist and pathologist
Chemotherapy with drugs that cause moderate to severe nausea
Having a nausea severity above 3 cm using the 10 cm VAS scale
Healthy sense of smell
Being over 18 years old</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Having migraines and chronic headaches
Having a history of asthma and allergy to rosa damacena
History of drug and alcohol addiction
Having mental illness
Having liver and kidney disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 38 women with breast cancer participated in the study according to the inclusion criteria. Each participant was given a package containing 20ml dropper bottle (containing rose essence prepared by parsian (Medina Al-Nabi) Company with a purity of 40%) ، three pads (10 *10 cm ) and a pin. After completing chemotherapy ،it should be taugh to pour 6 drops of dropper bottle content after going to home،which include rose essence of 40%purity on the pad and every given pad for every turn،before serving each main meal(morning, noon, and night) during 24 hours in a 30cm distant of their nose attached to their collar of clothes by a pin.This procedure was performed three times a day (morning, noon, and night). After the intervention (24 hours after chemotherapy), by phone Or face-to-face، Rhodes and VAS questionnaires are filled out to measure nausea and vomiting and sent to the data analyst.</i_keyword>
      <i_keyword>Control group: 38 women with breast cancer who participated in the study according to inclusion criteria. A package containing a 20 ml dropper bottle ( containing distilled water), three pads (10 x 10 cm) and a pin given to participants . After completing chemotherapy it shoud be taugh  to Pour 6 drops of the contents of the dropper bottle after going to home،which include distilled water on the pad and every given pad for every turn،before serving each main meal(morning, noon, and night) during 24 hours in a 30cm distant of their nose attached to their collar of clothes by a pin.This procedure was performed three times a day (morning, noon, and night) After the intervention (24 hours after chemotherapy), by phone Or face-to-face Rhodes and VAS questionnaires are filled out to measure nausea and vomiting and sent to the data analyst.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of Nausea. Timepoint: 15 minutes before the start of chemotherapy (initially study) and 24 hours after the intervention. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>The frequency of vomiting. Timepoint: 15 minutes before the start of chemotherapy (initially study) and 24 hours after the intervention. Method of measurement: Rhodes Index.</prim_outcome>
      <prim_outcome>The frequency of retching. Timepoint: 15 minutes before the start of chemotherapy (initially study) and 24 hours after the intervention. Method of measurement: Rhodes Index.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Amount of vomiting. Timepoint: 15 minutes before the start of chemotherapy (initially study) and 24 hours after the intervention . Method of measurement: Rhodes Index.</sec_outcome>
      <sec_outcome>Distress score of vomiting. Timepoint: 15 minutes before the start of chemotherapy (initially study) and 24 hours after the intervention. Method of measurement: Rhodes Index.</sec_outcome>
      <sec_outcome>Distress score of retching. Timepoint: 15 minutes before the start of chemotherapy (initially study) and 24 hours after the intervention. Method of measurement: Rhodes Index.</sec_outcome>
      <sec_outcome>Total score of retching. Timepoint: 15 minutes before the start of chemotherapy (initially study) and 24 hours after the intervention. Method of measurement: Rhodes Index.</sec_outcome>
      <sec_outcome>Total score of vomiting. Timepoint: 15 minutes before the start of chemotherapy (initially study) and 24 hours after the intervention. Method of measurement: Rhodes Index.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-11-22</approval_date>
        <contact_name>Ethics committe of Arak University of Medical Sciences</contact_name>
        <contact_address>Code3848176341 ,Arak University of Medical Sciences،Next to Amir Al-Momenin Hospital، Basij Square،Phone:086-34173639 Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
